Cesitrx, (Liquid Cesium-131 Solution) for Use With Gliasite Rts
Source, Brachytherapy, Radionuclide. 510(k) K132996, from Isoray, Inc. (Richland, WA). Product code KXK, class 2.
As of Nov 20, 2026, K132996 is an FDA 510(k) held by Isoray, Inc., substantially equivalent on Dec 17, 2013 after 84 days, with no recalls tied to it in FDA's recall database.
- Review time: 84 days
- Recalls: 0
The GliaSite RTS with Cesitrex, (Liquid $^{131}$CsCl), is intended to deliver intracavity radiation therapy (brachytherapy) in patients with malignant brain tumors following tumor resection surgery.
- Gliasite RtsK111931 · Isoray Medical, Inc. · Aug 5, 2011
- OncoPatchK252296 · Oncopatch, Inc. · Dec 5, 2025
- IsoSphereK242818 · Isoaid, LLC · Jul 15, 2025
- RadianceTx Radionuclide Brachytherapy SourceK223465 · Radiance Therapeutics, Inc. · Jan 11, 2023
- GammaTileK221539 · Gt Medical Technologies · Nov 9, 2022
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Sep 24, 2013
- Review panel
- Radiology
- Regulation
- 21 CFR 892.5730
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files